Lactobacillus gasseri for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Lactobacillus gasseri for Health & Longevity

Created on 09/05/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A gut bacterium sold as a probiotic in several versions, each developed for a different purpose. The strongest human evidence: a modest reduction in deep abdominal fat with daily use over about three months, better sleep, and lower anxiety in adults under stress. Well tolerated. Strains are not interchangeable, and almost every trial was paid for by the sellers. (Full Review)

Protocol

Strain matched to the goal
Named strain, not the species
SBT2055 and BNR17 for visceral fat, CP2305 for sleep and stress, OLL2716 (LG21) for upper-stomach symptoms, PA-3 for uric acid, 345A for constipation. Strains are not interchangeable.
Doses used in the trials
1 × 1010 CFU/day
SBT2055 at 106–108 CFU/g in 200 g/day fermented milk; BNR17 at 1 × 1010 CFU/day in capsules; CP2305 at 1 × 1010 heat-inactivated cells/day; OLL2716 in 112 g yogurt twice daily.
Duration before judging
12 weeks
All the pivotal trials ran 12 weeks except the stress work, which ran 5 to 24 weeks. Assessment earlier than eight weeks reproduces none of the trial conditions.
Time to effect
Visceral fat
12 weeks or later
Assessed at 12 weeks or later; no trial reports meaningful change before eight weeks.
Sleep
2–5 weeks
Sleep measures moved within two to five weeks.
Stress
2–5 weeks
Stress measures moved within two to five weeks.

Benefits

Contraindications
  • Absolute neutrophil count below 0.5 × 109/L
  • Any active cytotoxic chemotherapy cycle
  • Central venous catheter or implanted intracardiac device in situ, prosthetic or non-native heart valves
  • Within 90 days of solid-organ transplantation, or on multi-agent immunosuppression
  • Short bowel syndrome or documented D-lactic acidosis
  • Intensive-care admission, or active injection drug use
  • Advanced cirrhosis at Child-Pugh Class C
    •
Key Interactions
  • Antibiotics (amoxicillin, clarithromycin, metronidazole, ciprofloxacin)
  • Immunosuppressants (tacrolimus, ciclosporin, mycophenolate, prednisone at or above 20 mg/day)
  • Proton pump inhibitors and antacids (omeprazole, esomeprazole, calcium carbonate)
  • Loperamide and other antimotility agents
  • Prebiotic fibre supplements (inulin, fructooligosaccharides, galactooligosaccharides)
  • Supplements with additive effects (berberine, green tea catechins, melatonin, magnesium glycinate, L-Theanine)
  • Antimicrobial botanicals (berberine, oregano oil, allicin)
  • Other interventions (faecal microbiota transplantation, bowel-preparation purgatives, gastrointestinal surgery)

Risk & Side Effects

  • Medium: Invasive infection in immunocompromised or device-carrying hosts
  • Low: Transient gas, bloating and loose stools; brain fog and bloating with small-intestinal bacterial overgrowth; symptoms from the fermented-milk vehicle
  • Speculative: Transfer of antibiotic-resistance genes; unwanted immune activation in autoimmune disease

Monitoring

Marker Target Why
Waist circumference Below 94 cm in men, below 80 cm in women Cheapest proxy for the fat depot the trials moved
Visceral fat area Below 100 cm² The actual endpoint of the fermented-milk trials
High-sensitivity C-reactive protein Below 1.0 mg/L Tests the inflammation arm of the proposed mechanism
Serum uric acid 3.5–5.5 mg/dL Endpoint of the PA-3 trial and a gout risk marker
Pittsburgh Sleep Quality Index Global score of 5 or below Primary endpoint of the pooled sleep analysis
Urea breath test for Helicobacter pylori Negative Decides which stomach protocol applies
Vaginal pH 3.8–4.5 Cheap proxy for lactobacillus dominance
Alanine aminotransferase Below 25 U/L in men, below 20 U/L in women Liver safety screen during long-term use
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Kidney safety screen during long-term use
Absolute neutrophil count 1.8–7.0 × 109/L Identifies the immune state in which live organisms are contraindicated

Cadence: Symptom scores at 4 and 8 weeks; primary body or laboratory measure at 12 weeks; then every 6 to 12 months while use continues.

Qualitative Assessment

  • Morning alertness and time to feel functional after waking
  • Subjective sleep depth and number of night wakings
  • Upper-abdominal fullness, early satiety and reflux frequency after meals
  • Gas, bloating and stool form, especially during the first two weeks
  • Cognitive clarity, since fogging is the signal that argues for a stop test
  • Perceived stress load and irritability under a known stressor
  • Belt notch or trouser fit, which tracks the waist change more sensitively than scale weight
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.